Laddar populära aktier...
The company changed its strategy and abandons its plans to build 600MW of own wind power capacity.
Redeye comments on Fluoguide raising cSEK60m through a directed share issue.
Marknadens nedgång träffar till slut med full kraft, så ledningen revar seglen och vi sänker prognos...
Q2 report due 18 July We forecast SEK 561m net sales, SEK 81m EBITA Fair value range raised to SEK 4...
Q2e: sales +18% and EBITDA +38% y-o-y We raise our EBITDA estimates by 10-6% on '24e-'26e Positive E...
Analyst Group har med Refine Group ingått avtal om kontinuerlig analysbevakning, innefattande bl.
Redeye leaves a comment following Lipum’s announcement of further clinical advancements in the ongoi...
VNV Global är investmentbolaget som ger en unik möjlighet till att få exponering mot onoterade snabb...
Redeye is encouraged by the news that Kontigo Care is launching Previct Safety—a digital drug test s...
Q2e: 0% organic growth and stable margins Higher central costs behind 3-2% cuts to adj.
Circio presents a scientific update on the pre-clinical work with the circular RNA platform.
Starkt kv2 2024 förväntas Fable Media Group AB (”FMG” eller ”Bolaget”) Meddelade på torsdagen den 1...
Under H1-24 har Luxbright AB (”Luxbright” eller ”Bolaget”) erhållit ordrar om ca 15 MSEK, och det ko...
Redeye comments on GiG’s acquisition of the SEO and content service supplier Titan Inc, which is exp...
Redeye embraces the not-so-unanticipated SEK50m directed share issue, giving the company additional ...